Prostate
Издатель: Wiley · ISSN 02704137 · 36 статей
-
The 32nd Annual Prostate Cancer Foundation Scientific Retreat Report
ABSTRACT Background The 32nd Annual Prostate Cancer Foundation (PCF) Scientific Retreat took place in Carlsbad, CA on October 23–25, 2025. Methods The Annual PCF Scientific Retreat is a global forum for presenting the newest basic,...
-
Burden of Prostate Cancer in the United States of America (USA): 1990–2023, Global Burden of Disease (GBD) Study 2023
ABSTRACT Importance Prostate cancer is the most frequently diagnosed non‐cutaneous malignancy and the second leading cause of cancer‐related mortality among men in the United States of America (USA). Despite long‐term improvements in...
-
Issue Information
The Prostate, Volume 86, Issue 16, Page 1537-1537, Deceamber 2026.
-
Androgen Receptor‐Immune Crosstalk in Metastatic Castration‐Resistant Prostate Cancer: From Context‐Dependent Remodeling to Biomarker‐Guided Translation
The Prostate, Volume 86, Issue 16, Page 1539-1555, Deceamber 2026.
-
Hot‐Flash Treatment During Androgen Deprivation Therapy Needs a Sleep‐and‐Mood Safety Check
The Prostate, Volume 86, Issue 16, Page 1687-1688, Deceamber 2026.
-
Cross‐Cohort Characterization of an LHB‐Associated Transcriptomic State in Prostate Cancer
The Prostate, Volume 86, Issue 16, Page 1664-1670, Deceamber 2026.
-
[177Lu]Lu‐PSMA‐617 Plus Short‐Course Priming With Enzalutamide in Metastatic Castration‐Resistant Prostate Cancer: A Single‐Arm Phase 2 Trial (Lu‐PRIME)
The Prostate, Volume 86, Issue 16, Page 1630-1636, Deceamber 2026.
-
Histological Prostatic Inflammation Is Associated With Storage Lower Urinary Tract Symptoms and Inflammatory/Fibrotic Marker Expression in Benign Prostate Biopsies
The Prostate, Volume 86, Issue 16, Page 1621-1629, Deceamber 2026.
-
Comparison of Gene Enrichment Between Prostate Tissue and Urine for Non‐Invasive Biomarker Development
The Prostate, Volume 86, Issue 16, Page 1653-1663, Deceamber 2026.
-
Neoadjuvant Hormonal Therapy Before Radical Prostatectomy: Favorable Pathological and PSA Outcomes Do Not Guarantee Favorable Oncological Outcomes
The Prostate, Volume 86, Issue 16, Page 1645-1652, Deceamber 2026.
-
Prognostic Value of MRI‐Derived Apparent Diffusion Coefficient in Intermediate‐Risk Prostate Cancer Treated With Definitive Radiotherapy
The Prostate, Volume 86, Issue 16, Page 1612-1620, Deceamber 2026.
-
Survival Outcomes by Frailty and Comorbidities in Veterans Treated With Abiraterone and Enzalutamide for Metastatic Castration‐Resistant Prostate Cancer
The Prostate, Volume 86, Issue 16, Page 1637-1644, Deceamber 2026.
-
Insulin‐Like Growth Factor Axis and Survival in Metastatic Hormone‐Sensitive Prostate Cancer: Post‐Hoc Analysis From the ENZAMET Phase 3 Trial
The Prostate, Volume 86, Issue 16, Page 1671-1680, Deceamber 2026.
-
GenProb‐PCSM: A Simplified Weighted Germline Score for Prostate Cancer‐Specific Mortality
The Prostate, Volume 86, Issue 16, Page 1604-1611, Deceamber 2026.
-
Defining a Safe Biopsy Deferral Strategy in Patients With Low‐Risk or Equivocal MRI Findings Using Prostate‐Specific Antigen‐Based Metrics
The Prostate, Volume 86, Issue 16, Page 1590-1603, Deceamber 2026.
-
Black Race Predicts Poor Compliance and Higher Prostate Cancer Risk in a Multinational Repeat Biopsy Cohort: Secondary Analysis From the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Clinical Trial
The Prostate, Volume 86, Issue 16, Page 1569-1576, Deceamber 2026.
-
Stereotactic Prostate Cancer Ablative Re‐Irradiation: A Systematic Review and Meta‐Analysis (SPARE)
The Prostate, Volume 86, Issue 16, Page 1556-1568, Deceamber 2026.
-
Is a Few Too Many? Alcohol Consumption and Prostate Cancer Upgrading During Active Surveillance
The Prostate, Volume 86, Issue 16, Page 1681-1686, Deceamber 2026.
-
Adult Levels of Testosterone Induce Prostatic Epithelial Hyperplasia During Mouse Prostate Development Through Puberty
The Prostate, Volume 86, Issue 16, Page 1577-1589, Deceamber 2026.
-
Non–Prostate Cancer‐Related Factors That Influence Serum Prostate‐Specific Antigen: A Narrative Review of 45 Non‐Malignant PSA Modifiers
ABSTRACT Background To consolidate into a single review more than forty non‐cancer‐related factors that have been found to elevate or reduce prostate‐specific antigen (PSA) levels in the peer‐reviewed literature, emphasizing their...
-
Prostatic Enlargement in Acromegaly Despite Preserved Lower Urinary Tract Function: A Cross‐Sectional Comparative Study
ABSTRACT Background Acromegaly is characterized by organomegaly driven by chronic GH/IGF‐1 excess, and the prostate gland may be affected as part of this generalized organ enlargement. Although prostatic enlargement has been documented...
-
Plasma Steroid Trajectories From Day‐of‐Surgery Baseline After Robot‐Assisted Radical Prostatectomy for Prostate Cancer
ABSTRACT Background Circulating steroid trajectories after robot‐assisted radical prostatectomy are poorly characterized from the day‐of‐surgery baseline, and relevant biology extends beyond testosterone and dihydrotestosterone to...
-
Hippo Pathway Modulation Alters the Proteome and Migratory Phenotype of Prostate Cancer Cells
ABSTRACT Background The Hippo pathway effector YAP1 has been implicated in prostate cancer progression, migration, and castration resistance, yet how pharmacological YAP1 inhibition reshapes the prostate cancer proteome remains...
-
Identification of Novel CD52+ Fibroblasts in Nodular Prostatic Hyperplasia
ABSTRACT Background Benign prostatic hyperplasia (BPH) and lower urinary tract symptoms are strongly associated with chronic prostate inflammation and stromal remodeling, yet the stromal cell programs that emerge during inflammatory,...
-
Subsequent Detection of Clinically Significant Prostate Cancer After Suspicious MRI and an Initial Biopsy Negative for csPCa: A Longitudinal Subgroup Analysis of the MULTIPROS Trial
ABSTRACT Background Management after suspicious multiparametric MRI (mpMRI; PI‐RADS ≥ 3) and an initial biopsy negative for clinically significant prostate cancer (csPCa) remains uncertain. We described the frequency of subsequent csPCa...
-
Age Does Not Independently Predict Biochemical Recurrence in Prostate Cancer Following Radical Prostatectomy: A Comparative Analysis of 4223 pT2N0R0 Patients
ABSTRACT Background Whether younger age independently predicts biochemical recurrence (BCR) after radical prostatectomy (RP) remains controversial because previous studies have included heterogeneous pathological stages and treatment...
-
Real‐World HRR Testing Pathways and Patterns of Detected Alterations in Prostate Cancer From the Multinational ARON‐3 Study
ABSTRACT Background Homologous recombination repair (HRR) testing is increasingly relevant in prostate cancer because it identifies patients who may benefit from biomarker‐guided treatment strategies, including poly(ADP‐ribose)...
-
Circulating Tumor Cell Synaptophysin and Androgen Receptor Expression Reflect Prostate Cancer Phenotypes in Metastatic Disease
ABSTRACT Background Chronic exposure to androgen receptor (AR)‐targeted therapies can drive lineage plasticity, leading to treatment resistance and neuroendocrine prostate cancer (NEPC), characterized by loss of AR expression and...
-
Exploratory Analysis of Peri‐Prostatic Adipose Tissue Radiomics Features and Their Potential to Predict Prostate Cancer Diagnosis: Results From a UK Biobank Study
ABSTRACT Introduction This paper reports the development and application of an artificial intelligence (AI)–led approach to large volume MRI data curation and image segmentation of periprostatic adipose tissue (PPAT) in prostate cancer...
-
Evaluation of Time to Metastasis After Prostatectomy as a Prognostic Factor in Patients With Metachronous mHSPC: A Secondary Analysis of the SWOG‐1216 Phase 3 Trial
ABSTRACT Background The prognostic significance of time to metastasis (TTM) following radical prostatectomy in patients with metachronous metastatic hormone‐sensitive prostate cancer (mHSPC) remains uncertain. We performed a secondary...